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BACKGROUND: We evaluated bevacizumab with metronomic etoposide among recurrent malignant glioma patients in a phase 2,
open-label trial.
METHODS: A total of59 patients, including 27 with glioblastoma (GBM) and 32 with grade 3 malignant glioma, received 10mgkg
 1
bevacizumab biweekly and 50mgm
 2 etoposide daily for 21 consecutive days each month. The primary end point was a 6-month
progression-free survival, and secondary end points included safety and overall survival. Vascular endothelial growth factor (VEGF),
VEGFR-2, carbonic anhydrase 9 (CA9) and hypoxia-inducible factor-2a (HIF-2a) were assessed semiquantitatively in archival tumours
using immunohistochemistry and were correlated with outcome.
RESULTS: Among grade 3 and GBM patients, the 6-month progression-free survivals were 40.6% and 44.4%, the radiographic response
rates were 22% and 37% and the median survivals were 63.1 and 44.4 weeks, respectively. Hypertension predicted better outcome
among both grade 3 and GBM patients, whereas high CA9 and low VEGF were associated with poorer progression-free survival
(PFS) among those with GBM. The most common grade X3 adverse events included neutropaenia (24%), thrombosis (12%),
infection (8%) and hypertension (3%). Two patients had asymptomatic, grade 1 intracranial haemorrhage and one on-study death
occurred because of pulmonary embolism.
CONCLUSION: Bevacizumab with metronomic etoposide has increased toxicity compared with previous reports of bevacizumab
monotherapy. Its anti-tumour activity is similar to that of bevacizumab monotherapy or bevacizumab plus irinotecan.
(ClinicalTrials.gov: NCT00612430).
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Malignant gliomas, including the most common subtype, grade
4 glioblastoma (GBM), as well as WHO grade 3 tumours such as
anaplastic astrocytoma (AA), remain essentially fatal malignancies
(Wen and Kesari, 2008). The median survival for GBM patients is
o15 months after external beam radiotherapy and temozolomide
after maximal safe resection (Stupp et al, 2005), whereas survival
for most grade 3 patients is 2–3 years (See and Gilbert, 2004).
Profound angiogenesis, a hallmark of malignant glioma, results
from a ‘perfect storm’ of hypoxia and hypoxia-independent
aberrant activation of cell signalling pathways that markedly
upregulate vascular endothelial growth factor (VEGF) expression
(Jain et al, 2007). Anti-angiogenic strategies targeting VEGF are
active among recurrent GBM patients. Daily administration of
AZD2171 (cediranib, AstraZeneca Pharmaceuticals, London, UK),
a potent oral, pan-VEGF receptor inhibitor that also inhibits
platelet-derived growth factor (PDGF) receptor and c-Kit, achieved
an overall radiographic response (ORR) of 56% and a median
progression-free survival (PFS) of 3.96 months (Batchelor et al,
2007). Bevacizumab, a humanised monoclonal antibody against
VEGF (Avastin, Genentech Pharmaceuticals, South San Francisco,
CA, USA), was originally reported to achieve dramatic radio-
graphic responses when combined with the topoisomerase-1
inhibitor irinotecan among recurrent GBM patients (Stark-Vance,
2005). In a formal phase II study of this regimen, Vredenburgh
noted a 61% ORR, 46% 6-month PFS (6-PFS) and a median overall
survival (OS) of 10 months among heavily pre-treated, recurrent
GBM patients (Vredenburgh et al, 2007a,b). The anti-tumour
activity of bevacizumab with and without irinotecan was
confirmed in two follow-up, prospective studies (Friedman et al,
2009; Kreisl et al, 2009) that recently led to accelerated approval
of bevacizumab monotherapy for recurrent GBM by the US
Food and Drug Administration. In addition, we have also recently
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rent grade 3 malignant glioma patients (Desjardins et al, 2008).
These studies, as well as additional retrospective series (Bokstein
et al, 2008; Kang et al, 2008; Zuniga et al, 2009), have also
confirmed the safety profile of this regimen for malignant glioma
patients.
This study was conducted to evaluate the anti-tumour activity
of etoposide, a topoisomerase-2 inhibitor, when administered on
a protracted, oral, ‘metronomic’ dosing schedule, in combination
with standard bevacizumab administration. Etoposide has modest
activity among recurrent malignant glioma patients as either
single-agent therapy or in combination with other chemo-
therapeutics (Chamberlain and Grafe, 1995; Fulton et al, 1996;
Kesari et al, 2007). We hypothesised that etoposide administered
on protracted, daily schedule may exert an effect as a metronomic
chemotherapeutic (Kerbel and Kamen, 2004) and thereby enhance
the anti-angiogenic and anti-tumour effect of bevacizumab in this
patient population.
PATIENTS AND METHODS
Protocol objectives
Our primary objective was to estimate the 6-month PFS among
adults with recurrent malignant glioma treated with protracted,
oral etoposide plus bevacizumab. Secondary objectives included
evaluation of the safety and tolerability of this regimen and
evaluation of the radiographic response, PFS and OS associated
with this regimen in this patient population.
Patient eligibility
Patients were required to have histological confirmation of grade
3 or 4 malignant glioma that was recurrent after previous radiation
or chemotherapy. Patients with previous low-grade glioma were
eligible if histological transformation to malignant glioma was
confirmed. Eligible patients were also at least 18 years of age, had a
Karnofsky performance status (KPS) X60% and were on a stable
corticosteroid dose for at least 1 week. Additional enrollment
criteria included: haematocrit 429%; absolute neutrophil count
41500 cellsml
 1; platelet count 4100000 cellsml
 1; and serum
creatinine o1.5mg per 100 ml, aspartate aminotransferase and
bilirubin o1.5 times the institutional upper limit of normal.
At least 4 weeks between surgical resection or chemotherapy, and
at least 12 weeks between radiotherapy, and enrollment were
required. All patients provided informed consent.
Patients were excluded for: 43 recurrences; uncontrolled
hypertension; therapeutic anticoagulation use; acute haemorrhage
on baseline MRI; urine protein:creatinine ratio 41; pregnancy
or nursing; previous bevacizumab or etoposide; active infection
requiring intravenous antibiotics; and previous stereotactic radio-
surgery, radiation implants or radiolabelled monoclonal antibody
therapy, unless there was unequivocal disease progression (such
as a new lesion or biopsy-proven recurrence).
Treatment design
Patients were stratified by histopathology into those with GBM and
those with grade 3 malignant glioma. All patients were adminis-
tered 50mgm
 2 of etoposide daily for 21 consecutive days of each
28-day cycle. Bevacizumab was administered at 10mgkg
 1
intravenously every 14 days. Study therapy was planned to
discontinue after 12 cycles. However, patients were given the
option to continue study therapy for 6 additional months if they
were felt to potentially derive further therapeutic benefit.
Specifically, such patients included those who had ongoing
radiographic or clinical improvement after 12 months or those
who had persistent contrast enhancement that was accompanied
by hypermetabolic activity on [
18F]fluorodeoxyglucose positron
emission tomography (
18FDG-PET) imaging. Study therapy was
discontinued for unacceptable toxicity, tumour progression, study
non-compliance or consent withdrawal.
Response evaluation
Study investigators determined response by neurological exami-
nation and contrast-enhanced MRI previous to every other
treatment cycle. A complete response (CR) required disappearance
of all enhancing tumours with corticosteroid discontinuation and
neurological stability or improvement. A partial response (PR)
required X50% reduction in size (product of largest perpendicular
diameters) of enhancing tumour with stability or improvement
of neurological status and corticosteroids. Complete and partial
responses also required stable or improved signal abnormality
on fluid-attenuated inversion recovery (FLAIR) sequences and
confirmation on consecutive scans at least 4 weeks apart.
Progressive disease (PD) was defined by any of the following:
X25% increase on enhancing tumour; a new enhancing lesion;
or clear worsening of FLAIR signal abnormality or significant
clinical decline that was not attributable to co-morbid event or
concurrent medication. Stable disease was defined as any
assessment not meeting CR, PR or PD criteria. The inclusion
of FLAIR signal changes in the classification of response in this
study was based on the growing recognition that some malignant
glioma patients undergoing therapy with VEGF or VEGFR
inhibitors may have significant improvement in contrast enhan-
cement, yet have extensive progressive changes on T2 or FLAIR
sequences, often accompanied by marked neurological
decline, which is felt to be indicative of progressive infiltrative
tumour (Bokstein et al, 2008; Norden et al, 2008; van den Bent
et al, 2009).
Dose modification and retreatment criteria
Daily etoposide dose was reduced by 25mg for grade 3 thrombo-
cytopenia, grade 4 neutropaenia or other related grade X3
non-haematologic events. Bevacizumab was discontinued for
uncontrollable hypertension, grade 2 or greater haemorrhage,
arterial thrombosis, wound dehiscence requiring surgical inter-
vention, intestinal perforation, grade 4 venous thrombosis,
proteinuria or congestive heart failure. Bevacizumab was held
until other grade 3, related events resolved to a grade p 1.
Initiation of each cycle required an absolute neutrophil count
(ANC) X1000mm
 3; a platelet count X100000mm
 3; aspartate
aminotransferase (AST), bilirubin and creatinine less than twice
the institutional upper limit of normal; and resolution of any
related grade X3 event to a grade p1.
Tumour marker analysis
Immunohistochemistry staining of archival, paraffin-embedded
tumour sections was performed and analysed for VEGF, VEGFR-2/
KDR as well as two markers of hypoxia, hypoxia-inducible factor
2a (HIF-2a) and carbonic anhydrase 9 (CA9), as previously
described (Sathornsumetee et al, 2008) by a neuropathologist who
was unaware of clinical and imaging outcome. A semiquantitative
score was derived from an intensity score of the reactivity product
(absent, 0; mild, 1; moderate, 2; strong, 3) related with endogenous
positive controls multiplied by distribution score (percentage of
reactive cells in tumour).
Statistical considerations
The primary aim of this study was to evaluate the 6-PFS rate of
bevacizumab plus protracted, oral etoposide among recurrent
malignant glioma patients. Yung et al (2000) reported a 6-PFS rate
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sof 21% (95% CI 13–29) among recurrent GBM patients treated
with temozolomide at first recurrence. Given that the prognosis of
our patient population was expected to be poorer than that
reported by Yung et al, the sample size goal of 27 GBM patients for
this study was chosen to provide 82% power to differentiate
between 6-PFS of 5 and 20% with a type I error of 0.04. Similarly,
the 6-PFS of temozolomide for recurrent grade 3 malignant glioma
patients as reported by Yung et al is 46% (95% CI 38–54). Given
that the prognosis of our grade 3 patients was again expected to be
poorer than that reported, a sample size goal of 32 recurrent grade
3 patients was chosen to provide 80% power to differentiate
between a 6-PFS of 20 and 40% with a type I error rate of 0.04. The
benchmark set by temozolomide was chosen as the historical
comparator for our study rather than the outcome reported on
previous bevacizumab studies because the latter had not been
validated in a multi-institutional setting when this study was
designed.
‘Stopping rules’ for poor efficacy and unacceptable toxicity were
incorporated for each stratum. Specifically, if X10 of the first 16
patients per stratum progressed or died within 2 months of study
initiation, further accrual would be suspended. In addition, if 6 or
more of the first 16 patients per stratum experienced unacceptable
toxicity, defined as grade X4 non-haematological events, further
accrual would be suspended.
Progression-free survival and OS were measured from the
cycle 1 start date and summarised using Kaplan–Meier estimator
including 95% CIs. For each cohort, PFS distribution was
compared between the following subgroups using the log-rank
test: patients o50 years old vs those X50 years; patients with a
KPS o90 vs those with a KPS X90; patients with 41 previous
episode of progression vs those with 1 previous progression; and
patients who received 41 previous chemotherapeutic vs those
who received only 1 previous chemotherapeutic. We also sought
to determine whether hypertension was associated with outcome.
For these purposes, hypertension was defined as sustained grade 1
for at least 4 weeks, grade X2 or the initiation or increase in anti-
hypertensive medications. Log-rank tests were conducted com-
paring patients who developed hypertension with those who did
not relative to OS and PFS.
The effect of each tumour marker on overall and PFS was
evaluated using separate Cox’s proportional hazard models.
Hazard ratios and the P-value from Wald’s chi-square tests were
determined for each model. The effect of each tumour marker
(CA9, VEGF, VEGFR-2 and HIF2a) on PFS-6 and radiographic
response was evaluated using logistic regression models. Odds
ratios and the P-value from Wald’s chi-square tests were
determined for each model. The effect of each categorical marker
on PFS-6 and radiographic response was also estimated using
Fisher’s exact test.
RESULTS
Patient characteristics
A total of 59 patients were enrolled between April 2007 and
January 2008, including 32 with grade 3 malignant glioma and
27 with GBM (Table 1).
Most patients had bulky disease at enrollment, given that
only 7% underwent a gross total resection of enhancing disease
before enrollment. Patients who underwent a GTR were not
evaluable for radiographic response. In general, patients were
significantly pretreated with 53% enrolling at either second or
third progression, whereas 73% had received two or more previous
chemotherapeutic agents.
As of 15 May 2009, four GBM patients (15%) remain alive,
including three with progressive disease and one with stable
disease in the tenth month of the study therapy. Again, 16 grade
3 malignant glioma patients (50%) remain alive, including 2 who
continue on-study therapy, 5 who are off study without recurrence
and 9 with progressive disease. In total, 39 patients (66%) have
died. Median follow-up was 91.2 weeks for GBM patients, and
69.9 weeks for grade 3 malignant glioma patients.
Study drug administration and safety
Study drug administration and compliance with treatment for
the intent-to-treat (ITT) study population were excellent. A total
of 389 cycles of therapy were administered, including a median
of 6.6 (range 1–18) cycles for the grade 3 malignant glioma
patients and 6.6 (range 1–20) cycles for the GBM patients,
respectively.
All patients were assessable for toxicity. As the adverse event
profiles were similar for both patient cohorts, a pooled summary of
toxicity is provided in Table 2. Significant haematological toxicity
included neutropaenia (grade 3, n¼9 (15%); grade 4, n¼5 (8%)),
thrombocytopaenia (grade 3, n¼2 (3%)) and anaemia (grade 3,
n¼1 (2%)). Most non-haematologic toxicities were of grade 2.
The most common serious non-haematologic events were throm-
bosis (grade 3, n¼4 (7%); grade 4, n¼2 (3%); grade 5, n¼1
(2%)), infection (grade 3, n¼4 (7%); grade 4, n¼1 (2%)) and
hypertension (grade 3, n¼1 (2%); grade 4, n¼1 (2%)).
Haemorrhage was limited to two patients with grade 1 central
Table 1 Patient characteristics
Tumor grade 3 (n¼32) 4 (n¼27)
Age, median (years) 45.9 54.3
Range (years) 24.5–61.7 24.1–70.4
Gender, male 19 (59%) 17 (63)
Female 13 (41%) 10 (37)
KPS
90–100 25 (78%) 19 (70)
70–80 7 (22%) 8 (30)
Diagnosis
GBM 27 (100)
AA 18 (56%)
AO 13 (41%)
PXA 1 (3%)
Time from diagnosis, median (weeks) 189.0 80.4
Range 11.3–1173.9 24–450
No. of previous PDs
1 14 (44%) 14 (52)
2 9 (28%) 8 (30)
3 9 (28%) 5 (19)
Previous XRT 32 (100%) 27 (100)
Surgery before enrollment
GTR 3 (9%) 1 (4)
STR 2 (6%) 0
Biopsy 2 (6%) 1 (4)
None 25 (78%) 25 (92)
No. of previous ChemoRx agents
1 10 (31%) 6 (22)
2 8 (25%) 8 (30)
3 7 (22%) 6 (22)
X4 7 (22%) 7 (26)
Abbreviations: AA¼anaplastic astrocytoma; AO¼anaplastic oligodendroglioma;
GBM¼glioblastoma; GTR¼gross total resection; KPS¼Karnofsky performance
status; PD¼progressive disease; PXA¼pilocytic xanthroastrocytoma; STR¼
subtotal resection; XRT¼radiotherapy. The numbers in parentheses refer to
percentage unless otherwise indicated.
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snervous system (CNS) bleeds detected on surveillance MRI, and
one patient with grade 2 GI bleeding from haemorrhoids. A single
on-study death, attributed to pulmonary embolism, occurred.
A total of nine grade 3 malignant glioma patients (28%) required
etoposide dose modification, including eight patients for grade
3 or 4 neutropaenia and one patient with grade 2 peripheral
neuropathy. Two GBM patients (7%) required etoposide dose
modification including one for grade 4 neutropaenia and one for
peripheral neuropathy. Four patients (13%) on the grade 3 arm
discontinued therapy because of toxicity including one patient
with persistent grade 3 proteinuria after 14 cycles of therapy,
1 patient with dehiscence of a previously healed craniotomy
incision after 7 cycles of therapy and the two patients described
above with grade 1 CNS haemorrhage. Three GBM patients (11%)
discontinued therapy because of adverse events, all of whom had
pulmonary emboli.
Outcome
The median OS, PFS, 6-PFS rate and the rate of radiographic
response are summarised in Table 3 and Figure 1. Outcome
comparisons were not performed for subsets of grade 3 malignant
glioma patients because of the small sample size. Complete and
partial responses were observed in one (4%) and five (19%) GBM
patients, and two (7%) and five (17%) grade 3 patients. Stable
disease was the best response in 19 (73%) and 21 (72%) of GBM
and grade 3 patients, respectively, whereas only two GBM (7%)
and four grade 3 (13%) patients progressed at first evaluation.
In total, 10 patients (17%) completed 12 cycles of therapy and eight
of these patients (80%) had no evidence of hypermetabolic activity
on [
18F]FDG-PET imaging (Figure 2A). Among six patients (10%)
who completed 1 year of planned therapy, five remain alive,
including four without tumour recurrence (all grade 3 malignant
glioma) and one (GBM) with recurrent tumour; one GBM patient
who completed a year of therapy subsequently died of progressive
tumour.
Although limited by sample size, the development of grade X1
hypertension was linked with improved outcome. Among GBM
patients who developed hypertension, median OS was not reached
and 1-year OS was 100%, whereas median and 1-year OS were 39.4
weeks and 34.8%, respectively, for those who did not develop
hypertension (P¼0.0095). A trend towards improved OS was also
noted among grade 3 patients who developed hypertension and all
of these patients also remain alive. In addition, PFS was longer for
grade 3 patients who developed hyptertension (P¼0.024). Among
GBM patients, median and 6-PFS were 61 weeks and 100%,
respectively, for those who developed hypertension when com-
pared with 16 weeks and 34.8% for those who did not; however,
these differences did not achieve statistical significance
(P¼0.123).
None of the demographic or pre-treatment characteristics had
an association with PFS within either patient cohort, although a
trend towards improved PFS was noted among grade 3 patients
with a KPS X90 (P¼0.054). In all, eight patients developed
hypertension (four GBM and four grade 3 MG, Table 2). A trend
towards improved survival was observed in these patients, but the
sample size was too small for subgroup analysis.
The 27 patients who achieved stable disease or radiographic
response were on corticosteroids at study initiation, and 10of them
(37%) decreased corticosteroids while on study, including five
patients (19%) who successfully tapered off corticosteroids
completely.
Tumour markers
In all, 12 GBM patients (44%) and 11 grade 3 malignant glioma
patients (34%) had adequate tumour material for marker
expression analysis (Supplementary Table 1, Supplementary
Figure 1). All tumours expressed VEGF and VEGFR2 but the
range of expression varied from 10 to 80% for VEGF and 2 to 80%
for VEGFR2. Carbonic anhydrase 9 was detected in 11 of 12 (92%)
GBM tumours (percentage of positive cells: 1–80%) and in 8 of
11 (73%) grade 3 tumours (range of positive cells: 1–40%).
Hypoxia-inducible factor-2a was detected in 8 of 8 GBM tumours
(range of positive cells: 0.01–4%) and in 8 of 10 grade 3 tumours
(range of positive cells: 0.1–20%). All markers were more
commonly expressed by GBM tumours compared with grade
3 tumours.
Low CA9 expression (p10% of cells; P¼0.04) and increased
VEGF expression (430% of cells; P¼0.006) were associated with
Table 3 A comparison of outcomes of this study with other prospective clinical trials
Number of patients RR (%) Median PFS (weeks) PFS-6 (%) Median OS (weeks) Reference Regimen
Grade 3
32 24 24 (16–33) 41 (24,57) 63.1 (36–N) Current study BV + etoposide
33 61 30 (21–60) 55 (36–70) 65 (32–99) Desjardins et al (2008) BV + CPT-11
GBM
27 23 18 (13–40) 44.4 (26–62) 46.4 (25–70) Current study BV + etoposide
35 57 24 (18–36) 46 (32–66) 42 (35–60) Vredenburgh et al (2007a,b) 7
85 28 17 (12–23) 43 (30–56) 36.8 (33–43) Friedman et al (2009) BV monotherapy
82 38 22 (18–25) 50 (37–64) 34.8 (31–44) Friedman et al (2009) BV + CPT-11
48 35 16 (12–26) 29 (18–48) 31 (21–54) Kreisl et al (2009) BV monotherapy
Abbreviations: BV¼ bevacizumab; GBM¼glioblastoma; OS¼overall survival; PFS¼progression-free survival; PFS-6¼progression-free survival at 6 months. Numbers in
parentheses refer to available 95% confidence intervals.
Table 2 Frequency of adverse events observed in X10% of patients
Grade
Toxicity 2 3 4 5
Anaemia 11 (19%) 1 (2%)
Anoraexia 6 (10%)
Diarrhoea 6 (10%)
Fatigue 18 (31%) 1 (2%)
Hypertension 6 (10%) 1 (2%) 1 (2%)
Infection 13 (22%) 4 (7%) 1 (2%)
Mucositis 11 (19%)
Nausea/emesis 11 (19%)
Neutropaenia 15 (25%) 9 (15%) 5 (8%)
Proteinuria 6 (10%) 1 (2%)
Rash 6 (10%)
Thrombosis 4 (7%) 2 (3%) 1 (2%)
Transaminase elevation 6 (10%) 1 (2%)
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sbetter PFS among GBM patients (Supplementary Table 1). None of
the tumour markers were predictive of outcome among grade
3 tumours.
Pattern of failure
A total of 22 grade 3 malignant glioma patients (69%) and 21 GBM
patients (78%) developed radiographic evidence of progressive
disease. The pattern of recurrence included worsened enhance-
ment plus FLAIR changes at the primary tumour site in 15 (68%)
of the grade 3 patients and 13 (62%) GBM patients. Clinical decline
and progressive local FLAIR changes without worsened enhance-
ment were noted in four grade 3 patients (18%) and six GBM
patients (29%), respectively (Figures 2B and C). In addition, three
grade 3 patients (14%) and two GBM patients (10%) had new
distant sites of disease (defined as 42cm away from previous
enhancement without contiguous FLAIR signal abnormality) at
progression.
DISCUSSION
We report the first clinical trial evaluating metronomic chemo-
therapy combined with bevacizumab for recurrent malignant
glioma patients. We hypothesised that etoposide, administered on
a metronomic or protracted, daily dosing schedule would enhance
the anti-tumour activity of bevacizumab based on potentially
complimentary mechanisms of anti-angiogenic action. Bevacizu-
mab binds VEGF-A, preventing activation of VEGFR1 and
VEGFR2, whereas metronomic chemotherapy may exert an effect
through a number of anti-angiogenic actions, including induction
of endogenous angiogenesis inhibitors such as thrombospondin-1
(Damber et al, 2006), enhancement of endothelial cells apoptosis
(Bocci et al, 2002) and decreasing the mobilisation and viability
of circulating endothelial progenitor cells (Bertolini et al, 2003).
Preclinical studies confirm that metronomic etoposide is
preferentially cytotoxic against tumour endothelial cells compared
with tumour cells in vitro (Drevs et al, 2004), and that metronomic
etoposide plus anti-angiogenic therapy prolongs survival in
orthotopic, intracranial U87 GBM xenografts compared with
conventionally dosed chemotherapy with or without anti-angio-
genic therapy (Bello et al, 2001). Clinically, several studies using
metronomic dosing of etoposide have shown evidence of modest
activity among recurrent malignant glioma patients (Chamberlain
and Grafe, 1995; Fulton et al, 1996; Kesari et al, 2007), as well as
other cancer patient populations (Correale et al, 2006; Twardowski
et al, 2008). To date, the only published studies evaluating
metronomic chemotherapy plus bevacizumab have involved
patients with recurrent breast and ovarian cancer, and show
anticancer benefit (Dellapasqua et al, 2008; Garcia et al, 2008;
Garcia-Saenz et al, 2008).
Our study revealed that metronomic etoposide plus bevacizu-
mab has encouraging outcome when compared with established
benchmarks. Specifically, for recurrent GBM patients, our 6-PFS
rate and median OS were higher than those reported with
temozolomide at first recurrence (Yung et al, 2000), as well as
several studies with etoposide (Fulton et al, 1996; Chamberlain
and Kormanik, 1999) and historical series of salvage regimens.
(Wong et al, 1999; Ballman et al, 2007; Lamborn et al, 2008). In
addition, the outcomes of our study did not differ significantly to
that achieved with bevacizumab plus irinotecan in a single-
institution, phase 2 study (Vredenburgh et al, 2007b). It is
noteworthy that patients in that study as well as in this study were
heavily pretreated with a median of two previous episodes of
progressive disease.
A major remaining question is whether chemotherapy,
including metronomic, adds benefit over bevacizumab alone for
recurrent malignant glioma patients. Although a recently reported
phase II study randomised GBM patients at either first or second
recurrence to bevacizumab monotherapy or bevacizumab plus
irinotecan, this study was not powered to compare treatment
arms and randomisation served solely to eliminate treatment
assignment bias. The rate of radiographic response by blinded
centralised review and 6-PFS were 38 and 50% for patients treated
with combination therapy and 28 and 43% for those treated
with bevacizumab monotherapy. Although median OS did not
differ between the arms, monotherapy patients were also allowed
to crossover to the combination arm at progression and con-
tinue study therapy. Of concern, the overall toxicity appeared
increased in the combination cohort (Friedman et al, 2009).
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Figure 1 Kaplan–Meier plots of progression-free survival (A) and overall survival (B) for grade 3 malignant glioma and glioblastoma patients.
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FDG-PET
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Figure 2 Baseline and post-treatment magnetic resonance imaging of a representative, responding glioblastoma patient including post-contrast axial
T1-weighted and fluid-attenuated inversion recovery (FLAIR) images. [
18F]fluorodeoxyglucose positron-emission tomography imaging at the completion
of 12 cycles of therapy shows no evidence of hypermetabolic activity (arrow). (A) Baseline and off-study magnetic resonance imaging showing worsened
FLAIR signal abnormality, indicating an infiltrative, microscopic pattern of treatment failure (arrows) involving the isolateral hemisphere (B) and the
contralateral hemisphere (C), despite improved contrast enhancement.
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bevacizumab monotherapy among recurrent GBM patients (Kreisl
et al, 2009). The results of the current study are comparable with
those reported previously for bevacizumab-based therapy
(Table 3). Furthermore, the addition of chemotherapy to
bevacizumab, as shown in previous studies with irinotecan and
in this study with metronomic etoposide, can lead to increased
toxicity.
In this study we also noted that bevacizumab plus metronomic
etoposide is active among recurrent grade 3 malignant glioma
patients. It is noteworthy that there are no data with bevacizumab
monotherapy for this subset of malignant glioma patients, but our
study results compare favourably with those achieved with
bevacizumab plus irinotecan (Desjardins et al, 2008) (Table 3),
and are superior to those reported in two meta-analyses of salvage
regimens (Wong et al, 1999; Lamborn et al, 2008).
As noted in other clinical trials (Chamberlain and Grafe, 1995;
Fulton et al, 1996; Kesari et al, 2007), protracted daily etopo-
side was well tolerated and did not increase bevacizumab-
specific toxicity. Grade 3 or 4 neutropaenia, the most common
serious toxicity, occurred in approximately 24% of patients, but
responded to dose modification. Grade 3 or 4 anaemia and
thrombocytopaenia occurred rarely. The spectrum of non-
haematological toxicity was comparable with that previously
reported for bevacizumab in this patient population (Friedman
et al, 2009) and appeared more favourable than that reported
for bevacizumab plus irinotecan. Specifically, 7 patients (11%) in
the current study discontinued therapy because of toxicity,
whereas 11 patients (31%) in our single-institutional study
(Vredenburgh et al, 2007b) and 14 patients (18%) in the
randomised study (Friedman et al, 2009) discontinued bevacizu-
mab plus irinotecan because of toxicity.
Corticosteroids, which are routinely administered to brain tumour
patients to control symptoms due to cerebral oedema, cause a
multitude of adverse sequellae that diminish quality of life, including
marked weight gain, muscle loss, osteoporosis, hypertension,
dysregulated glucose metabolism and immunosuppression (Wen
et al, 2006). In this study, 37% of patients who were on chronic
corticosteroid administration at the time of enrollment were able to
taper their daily corticosteroid dose, including 19% who were able to
completely discontinue corticosteroids. A similar ability to decrease
chronic corticosteroid requirements has been noted in other studies
evaluating anti-VEGF/R therapeutics (Batchelor et al, 2007; Vreden-
burgh et al, 2007a,b; Desjardins et al, 2008).
Hypertension, a known complication of VEGFR signalling
inhibition, is likely related with several factors, including
diminished nitric oxide and prostacyclin synthesis (Scotland
et al, 2005), diminished endothelial baroreceptor response
(Yang et al, 2002), small artery and arteriole rarefaction (Ciuffetti
et al, 2003) as well as increased vascular stiffness (Veronese et al,
2006). To our knowledge, this is the first clinical trial among
malignant glioma patients to note an association between
hypertension after VEGF-targeted therapy and improved outcome.
However, this association should be interpreted cautiously and
may have been because of a statistical coincidence, given the
small number of patients who developed hypertension on this
study. Clearly, our results require further validation in subse-
quent clinical trials. Nonetheless, hypertension has been associated
with better outcome among other cancer patient populations
after bevacizumab (Rixe et al, 2007; Schneider et al, 2008; Scartozzi
et al, 2009), leading some to postulate that hypertension may
serve as a biomarker of response (Jubb et al, 2006; van Heeckeren
et al, 2007). Alternatively, it is possible that the development
of hypertension may simply reflect longer bevacizumab exposure.
We evaluated this possibility and noted that the interval from
study initiation to hypertension was 6.4 weeks for GBM patients
and 32 weeks for the grade 3 patients. The fact that both of
these values were considerably less than the median PFS observed
for each study cohort suggests that hypertension may be a
predictive marker rather than simply reflecting prolonged
bevacizumab exposure. We further analysed this association
by reviewing our previous bevacizumab plus irinotecan trial for
recurrent GBM (Vredenburgh et al, 2007b). In this series, similar
to the current study, there was a trend towards improved
median PFS, 6-PFS and OS among patients who developed
hypertension compared with those who did not, but this analysis
was also limited by small sample size. Nonetheless, further
evaluation of hypertension as a potential predictor of bevacizumab
activity among recurrent malignant glioma patients should be
considered.
Our evaluation of tumour marker expression and outcome were
clearly limited by the small number of analysed tumours as well as
the use of archival tumour samples. Nonetheless, we noted that
improved PFS was associated with lower CA9 expression as a
marker of tumour hypoxia. It is noteworthy that we previously
noted a similar association among recurrent malignant glioma
patients treated with bevacizumab and irinotecan (Sathornsumetee
et al, 2008). Of interest, we also noted that patients who had lower
levels of VEGF, the target of bevacizumab, VEGF, seemed to
respond less well with a lower PFS. Further analysis to validate
these findings should be considered.
Our group and others have noted that potent VEGF inhibitors
can decrease the permeability and intravenous contrast enhance-
ment within 24–48h (Batchelor et al, 2007; Desjardins et al, 2007).
Although radiographic response among malignant glioma
patients is traditionally based on changes in the largest
bi-dimensional product of enhancement after gadolinium admin-
istration (Macdonald et al, 1990), anti-VEGF therapy can
significantly and progressively worsen non-enhancing oedema on
MRI that may be due to infiltrative disease, despite stable or
even improved contrast-enhanced images (Ananthnarayan et al,
2008; Kang et al, 2008; Norden et al, 2008; Zuniga et al, 2009).
We observed this pattern of progression in 17% of patients in
the current study. Selection for a more invasive phenotype is
supported by preclinical studies that revealed increased ‘satellites’
of infiltrative tumour that co-opt normal host vessels in ortho-
topic GBM xenografts treated with a VEGF monoclonal anti-
body (Rubenstein et al, 2000). Furthermore, as noted by others
(Norden et al, 2008; Zuniga et al, 2009), we observed that new
distant disease occurs in approximately 10% of patients. More
diffuse, infiltrative, non-enhancing tumour at progression as well
as the emergence of new, distant CNS sites of disease suggest that
malignant gliomas may evolve resistance to VEGF-targeted
therapeutics by adopting a more invasive phenotype that is
relatively independent of VEGF signalling.
We performed the first study of bevacizumab administered
with a metronomic chemotherapeutic (etoposide) and show
that this regimen is safe and associated with encouraging clinical
and survival benefit among recurrent GBM and grade 3 malig-
nant glioma patients. Further studies evaluating this specific
regimen as well as others, combining a metronomic chemo-
therapeutic plus a VEGF/R inhibitor, should be considered.
Additional prospective studies to evaluate potential predictive
biomarkers of anti-VEGF therapy for malignant glioma patients,
including hypertension as well as tumour hypoxia and VEGF
expression, are appropriate. Finally increased understanding
of mechanisms of VEGF inhibitor resistance, including enhan-
ced invasion and infiltration, is critically needed to further
improve the outcome with anti-angiogenic therapy for malignant
glioma patients.
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